[Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis

Raghu, 2018, American Thoracic Society, European Respiratory Society Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, Am J Respir Crit Care Med, 198, e44, 10.1164/rccm.201807-1255ST Selman, 2014, Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model, Am J Respir Crit Care Med, 189, 1161, 10.1164/rccm.201312-2221PP Martinez, 2017, Idiopathic pulmonary fibrosis, Nat Rev Dis Primers, 3, 17074, 10.1038/nrdp.2017.74 Selman, 2020, The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis, Cell Signal, 66, 109482, 10.1016/j.cellsig.2019.109482 Cottin, 2018, Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases, Eur Respir Rev, 27, 180076, 10.1183/16000617.0076-2018 Wijsenbeek, 2020, Spectrum of fibrotic lung diseases, N Engl J Med, 383, 958, 10.1056/NEJMra2005230 Wijsenbeek, 2019, Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management, Curr Med Res Opin, 35, 2015, 10.1080/03007995.2019.1647040 George, 2020, Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities, Lancet Respir Med, 8, 925, 10.1016/S2213-2600(20)30355-6 Nasser, 2020, Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS® study), Eur Respir J, 17, 2002718 Gimenez, 2018, Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis, Thorax, 73, 391, 10.1136/thoraxjnl-2017-210035 Brown, 2020, The natural history of progressive fibrosing interstitial lung diseases, Eur Respir J, 55, 2000085, 10.1183/13993003.00085-2020 Olson, 2020, Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey, Adv Ther, 38, 854, 10.1007/s12325-020-01578-6 Ryerson, 2017, A standardized diagnostic ontology for fibrotic interstitial lung disease. An international working group perspective, Am J Respir Crit Care Med, 196, 1249, 10.1164/rccm.201702-0400PP Borie, 2017, Management of suspected monogenic lung fibrosis in a specialised centre, Eur Respir Rev, 26, 160122, 10.1183/16000617.0122-2016 Selman, 2021, When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases, Eur Respir J, 58, 2004507, 10.1183/13993003.04507-2020 Selman, 2021, From pulmonary fibrosis to progressive pulmonary fibrosis: a lethal pathobiological jump, Am J Physiol Lung Cell Mol Physiol, 321, L600, 10.1152/ajplung.00310.2021 Cutting, 2021, Family history of pulmonary fibrosis predicts worse survival in patients with interstitial lung disease, Chest, 159, 1913, 10.1016/j.chest.2021.01.026 Harari, 2020, Fibrotic interstitial lung diseases and air pollution: a systematic literature review, Eur Respir Rev, 29, 200093, 10.1183/16000617.0093-2020 López-Otín, 2013, The hallmarks of aging, Cell, 153, 1194, 10.1016/j.cell.2013.05.039 Selman, 2016, Aging and pulmonary fibrosis, Rev Invest Clin, 68, 75 Lee, 2021, Molecular markers of telomere dysfunction and senescence are common findings in the usual interstitial pneumonia pattern of lung fibrosis, Histopathology, 79, 67, 10.1111/his.14334 Yao, 2021, Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis, Am J Respir Crit Care Med, 203, 707, 10.1164/rccm.202004-1274OC Kato, 2020, Impaired myofibroblast dedifferentiation contributes to nonresolving fibrosis in aging, Am J Respir Cell Mol Biol, 62, 633, 10.1165/rcmb.2019-0092OC Hinz, 2020, Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases, Nat Rev Rheumatol, 16, 11, 10.1038/s41584-019-0324-5 Reyfman, 2019, Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis, Am J Respir Crit Care Med, 199, 1517, 10.1164/rccm.201712-2410OC Habermann, 2020, Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis, Sci Adv, 6, 10.1126/sciadv.aba1972 Joshi, 2020, A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF/M-CSFR signalling in monocyte-derived alveolar macrophages, Eur Respir J, 55, 1900646, 10.1183/13993003.00646-2019 Froese, 2016, Stretch induced activation of TGF-beta1 in pulmonary fibrosis, Am J Respir Crit Care Med, 94, 84, 10.1164/rccm.201508-1638OC Tschumperlin, 2018, Mechanosensing and fibrosis, J Clin Invest, 128, 74, 10.1172/JCI93561 Sellarés, 2020, Serum biomarkers in diffuse interstitial lung diseases, Arch Bronconeumol, 56, 349, 10.1016/j.arbres.2019.08.002 Kim, 2010, Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease, Eur Respir J, 35, 1322, 10.1183/09031936.00092309 Kim, 2020, Risk prediction model in rheumatoid arthritis-associated interstitial lung disease, Respirology, 25, 1257, 10.1111/resp.13848 Adegunsoye, 2019, Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases, Ann Am Thorac Soc, 16, 580, 10.1513/AnnalsATS.201807-443OC Harada, 2013, Prognostic significance of fibroblastic foci in usual interstitial pneumonia and non-specific interstitial pneumonia, Respirology, 18, 278, 10.1111/j.1440-1843.2012.02272.x Hanak, 2008, Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome, Respir Med, 102, 852, 10.1016/j.rmed.2008.01.012 Molina-Molina, 2018, Clinical implications of telomere dysfunction in lung fibrosis, Curr Opin Pulm Med, 24, 440, 10.1097/MCP.0000000000000506 Newton, 2019, Telomere length and genetic variant associations with interstitial lung disease progression and survival, Eur Respir J, 53, 1801641, 10.1183/13993003.01641-2018 Newton, 2016, Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive, Eur Respir J, 48, 1710, 10.1183/13993003.00308-2016 Juge, 2017, Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis, Eur Respir J, 49, 1602314, 10.1183/13993003.02314-2016 Ley, 2019, Rare protein-altering telomere-related gene variants in patients with chronic hypersensitivity pneumonitis, Am J Respir Crit Care Med, 200, 1154, 10.1164/rccm.201902-0360OC Chan, 2019, Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study, BMC Pulm Med, 19, 192, 10.1186/s12890-019-0943-2 Solomon, 2016, Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease, Eur Respir J, 47, 588, 10.1183/13993003.00357-2015 Inoue, 2020, Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype, Chest, 158, 646, 10.1016/j.chest.2020.03.037 Bowman, 2021, Biomarkers in progressive fibrosing interstitial lung disease: optimizing diagnosis, prognosis, and treatment response, Front Med (Lausanne), 8, 680997, 10.3389/fmed.2021.680997 Alqalyoobi, 2020, Circulating plasma biomarkers of progressive interstitial lung disease, Am J Respir Crit Care Med, 201, 250, 10.1164/rccm.201907-1343LE Butt, 2021, Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis, PLOS ONE, 16, e0247256, 10.1371/journal.pone.0247256 Ko, 2020, Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease, PLOS ONE, 15, e0244114, 10.1371/journal.pone.0244114 Stock, 2021, Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression, Respirology, 26, 461, 10.1111/resp.13988 Nishiyama, 2021, Human epididymis protein 4 is a new biomarker to predict the prognosis of progressive fibrosing interstitial lung disease, Respir Investig, 59, 90, 10.1016/j.resinv.2020.08.002 Machahua, 2018, Serum AGE/RAGEs as a potential biomarker in idiopathic pulmonary fibrosis, Resp Res, 19, 215, 10.1186/s12931-018-0924-7 Raghu, 2012, Idiopathic pulmonary fibrosis clinical research network. prednisone azathioprine, and N-acetylcysteine for pulmonary fibrosis, N Engl J Med, 366, 1968, 10.1056/NEJMoa1113354 Richeldi, 2014, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, N Engl J Med, 370, 2071, 10.1056/NEJMoa1402584 King, 2014, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, 370, 2083, 10.1056/NEJMoa1402582 Flaherty, 2019, Nintedanib in progressive fibrosing interstitial lung diseases, N Engl J Med, 381, 1718, 10.1056/NEJMoa1908681 Wells, 2020, Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial, Lancet Respir Med, 8, 453, 10.1016/S2213-2600(20)30036-9 Maher, 2020, Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial, Lancet Respir Med, 8, 147, 10.1016/S2213-2600(19)30341-8 Behr, 2021, Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial, Lancet Respir Med, 9, 476, 10.1016/S2213-2600(20)30554-3 King, 2020, The trouble with group 3 pulmonary hypertension in interstitial lung disease: dilemmas in diagnosis and the conundrum of treatment, Chest, 158, 1651, 10.1016/j.chest.2020.04.046 Waxman, 2021, Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease, N Engl J Med, 384, 325, 10.1056/NEJMoa2008470 Gibson, 2020, Advances in targeted therapy for progressive fibrosing interstitial lung disease, Lung, 198, 597, 10.1007/s00408-020-00370-1